Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07765745

Effect of Thymoquinone 0.2% Gel on Bone Density, Bone Width, and Socket Preservation After Tooth Extraction

This study aims to evaluate the clinical and radiographic effects of 0.2% Thymoquinone gel on bone density, bone width, and socket preservation after tooth extraction.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kafrelsheikh University

Kafr ash Shaykh, Kafrelsheikh, 33516, Egypt

Location status: Recruiting

Location contact

Mohammed M Hussein, MD

SUB_INVESTIGATOR

Muataz A Karimeh, Bachelor

CONTACT

[email protected]

00201027988331

Ola M El Borady, MD

SUB_INVESTIGATOR

About this study

Tooth extraction triggers a cascade of biological events which lead to significant remodeling of the alveolar ridge, frequently resulting in reductions in both bone width and height.

The concept of alveolar ridge preservation (ARP) has developed to address the bone resorption that follows extraction. ARP aims to maintain ridge dimensions and reduce the need for further augmentation before implant placement.

Among these, the small-molecule Thymoquinone (TQ), derived from Nigella sativa, has demonstrated significant osteogenic, anti-inflammatory, and antioxidant effects in preclinical studies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 18-50 years.
  • Both sexes.
  • Patients requiring extraction of upper posterior teeth will be recruited.

Exclusion criteria

  • Healthy subjects with intact sockets after extraction.
  • Normal mouth opening and good oral hygiene.
  • No systemic conditions affecting bone healing.

Treatment and study plan

Gel foam

Drug

Patients will receive gel foam only.

Thymoquinone gel + gel foam

Drug

Patients will receive 0.2% thymoquinone gel + gel foam.

Nano-formulated 0.2% thymoquinone gel + gel foam

Drug

Patients will receive nano-formulated 0.2% thymoquinone gel + gel foam.

Primary outcomes

  1. Change in alveolar bone density after tooth extraction

    Time frame: 3 months after tooth extraction

    Alveolar bone density will be assessed radiographically using cone-beam computed tomography (CBCT). The change in bone density from baseline to the specified postoperative assessment will be compared.

Secondary outcomes

  1. Change in alveolar bone width after tooth extraction

    Time frame: 3 months after tooth extraction

    Alveolar bone width will be assessed radiographically using cone-beam computed tomography (CBCT). The change in alveolar ridge width from baseline to the postoperative assessment will be measured.

  2. Change in alveolar ridge dimension after tooth extraction

    Time frame: 3 months after tooth extraction

    Alveolar ridge dimensions will be assessed radiographically using cone-beam computed tomography (CBCT). Changes in the dimensions of the alveolar ridge following tooth extraction will be measured and compared.

Study contacts

Contact information is provided by the study sponsor or research team.

Muataz A Karimeh, Bachelor

CONTACT

[email protected]

00201027988331

Sponsors and collaborators

Lead sponsor

Kafrelsheikh University

Other

Registry information

Official study title

Clinical and Radiographic Evaluation of the Effect of Thymoquinone 0.2% Gel on Bone Density, Bone Width, and Socket Preservation After Tooth Extraction

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 14, 2026
Registry last updated
Aug 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.